Gilead Sciences, Inc.

- Gilead does not expect sizable M&A or meaningful fundraising through debt or equity in the near term. - The company has about $5 billion in cash and leverage back to pre-Immunomedics levels. - Near-term capital allocation focuses on organic growth, licensing deals, and advancing pipeline assets. - Gilead will continue disciplined capital deployment and prioritizes internal investments over large acquisitions. - No indications of plans for equity fundraises or major debt issuance mentioned in the recent Q1 2024 earnings call transcript.

- Gilead plans to double its manufacturing capacity for cell therapy as outlined at the recent Kite analyst event, supporting expansion into new indications and disease areas with next-generation products. - The company will make incremental investments to support the launch of seladelpar post-CymaBay acquisition as well as other R&D efforts. - Capital allocation priorities remain disciplined with sufficient balance sheet flexibility; ordinary course licensing deals expected, but no sizable M&A anticipated in the near term. - Gilead will continue investing in its pipeline and clinical programs, including HIV innovations and oncology trials. - The company emphasizes disciplined expense management while funding growth initiatives across HIV, oncology, liver disease, and cell therapy. - No specific dollar figures for capex were disclosed, but expansion of manufacturing and commercialization infrastructure is ongoing.

- Gilead expects total product sales in 2024 to be in the range of $27.1 to $27.5 billion. - Excluding Veklury, base business product sales are expected to grow 4% to 6% year over year, reaching $25.8 to $26.2 billion. - HIV product sales anticipated to grow approximately 4% in 2024; however, HIV sales are expected to be roughly flat in 2025 due to the Medicare Part D redesign impact. - Overall business is expected to continue growing in 2025 despite headwinds in HIV. - Trodelvy sales surpassed $1 billion annually, with ongoing Phase 3 trials suggesting expansion into new indications and earlier lines of therapy. - Seladelpar, acquired via CymaBay, is expected to contribute modestly to 2024 sales with more meaningful growth in 2025 and beyond. - Kite's cell therapy business aims to grow through expanding treatment centers and innovative next-generation products. - Long-term outlook includes growth from HIV prevention advancements, oncology, cell therapy, and liver disease treatments.

- Full-year 2024 revenue guidance unchanged: Total product sales expected between $27.1B to $27.5B; base business sales (excluding Veklury) expected $25.8B to $26.2B, reflecting 4-6% growth year-over-year. - Expected diluted EPS for 2024 is in the range of $3.45 to $3.85, impacted by nondeductible charges from CymaBay acquisition; excluding charges, EPS is within guidance range shared earlier. - Operating expenses expected to decline mid-single-digits year-over-year; R&D expected to grow at higher end of low-to-mid single-digit range due to CymaBay incremental expenses. - SG&A expected modestly higher, reflecting CymaBay expenses but managed within operating expense guidance. - EPS dilutive in 2024 due to CymaBay deal but expected to breakeven in 2025 and become significantly accretive thereafter. - Margin expansion expected over time through disciplined expense management and top-line growth. - No specific 2025 EPS guidance yet; more details to come early next year.

The transcripts provided do not explicitly mention "Current," "Expected Orderbook," or "Pending Orders" in relation to Gilead Sciences. However, relevant insights regarding business outlook and sales expectations include: - Total product sales (excluding Veklury) grew 6% year over year to $6.1 billion in Q1 2024. - HIV product sales grew 4% year over year, supported by strong demand and pricing. - Oncology sales were up 18%, driven by key products like Trodelvy and cell therapies. - Liver disease sales increased 9%, with anticipated modest sales contribution from seladelpar in 2024 and more pronounced in 2025. - Veklury sales declined 3% year over year due to lower COVID-19 hospitalizations. - Management expects growth despite near-term headwinds like HIV Part D redesign affecting 2025. - Confident about returning to growth in cell therapy in the second half of 2024. - No specific order backlog or pending order figures were disclosed.